1. Top of page
  2. Abstract
  3. Acknowledgements
  4. Disclosure of Conflict of Interests
  5. References

Bonten TN, Snoep JD, Roest M, Rosendaal FR, van der Bom JG. Platelet reactivity is not associated with recurrent cardiovascular events in men with a history of myocardial infarction: a cohort study. J Thromb Haemost 2012; 10: 2616–8.

Cardiovascular disease is one of the leading causes of morbidity and mortality worldwide. In spite of improvements in secondary prevention over the past decades 20–40% of patients develop a recurrent event [1]. Platelets are key players in the development of arterial thrombosis. Consequently, a cornerstone of secondary prevention comprises the inhibition of platelets [2,3]. According to international guidelines, classic risk factors are aggressively treated after a first cardiovascular event. Yet, other biological mechanisms may play a role in developing a recurrent event. Platelet characteristics, such as increased basal reactivity, have been proposed to be one of those mechanisms. At the occurrence of arterial thrombosis, platelets are activated and release granule contents into the vasculature, including chemokines which interact with other blood cells and the endothelium [4,5]. Three of these chemokines are NAP-2 (neutrophil-activating peptide-2), which is an activation product of CXCL7 (CXC chemokine ligand 7, also known as precursor of beta-thromboglobulin), CXCL4 (CXC chemokine ligand 4, also known as platelet factor 4) and RANTES (regulated on activation, normal T cell expressed and secreted), which modulates monocytes involved in the progression of atherosclerotic plaques [6]. We measured NAP-2, CXCL-4 and RANTES because these markers were studied previously in relation to cardiovascular disease and serve as a marker of basal platelet activity [6–17]. We hypothesized that increased basal activity of these platelet markers increase the risk of a recurrent cardiovascular event. In the present study, we studied the association between plasma concentrations of NAP-2, CXCL4 and RANTES and the incidence of recurrent cardiovascular events in men with a history of a myocardial infarction (MI).

A cohort study was performed among men who experienced a first MI between 1990 and 1996. Details of the study have been reported previously [18]. In short, patients were followed until 1st September 2004 to assess the occurrence of recurrent major arterial cardiovascular events (rMACE). Follow-up information was collected from hospital files, general practitioners and patient questionnaires. The study was approved by the local ethics committee and all patients gave written informed consent. A blood sample was collected from each patient after the first event to determine levels of platelet markers (NAP-2, CXCL4 and RANTES) using semi-automated ELISA as described previously [12,19]. High levels of platelet reactivity were defined as levels above the 90th percentile. Continuous data are summarized as medians with interquartile range (IQR) and categorical data are presented as counts and percentages. Cox’s proportional hazard models were used to estimate hazard ratios for the occurrence of rMACE according to different concentrations of the platelet markers. Hazard ratios were adjusted for putative confounding factors in the relation between the platelet reactivity markers and rMACE. Sensitivity analyzes using continuous variables and different cut-off points were performed.

A total of 542 men were included in the cohort who experienced a first MI at a median age of 57 years (IQR 49–64), and for whom the median follow-up time was 9.2 years (IQR 2.7–11.4). During follow-up, 254 (47%) men developed at least one rMACE. The median time between first MI and blood sampling was 2.6 years (range 0.2–6 years), which did not differ between the patients with rMACE and no rMACE. Platelet reactivity markers were missing in 41 patients, of whom clinical characteristics did not differ from the non-missing patients. For all platelet reactivity markers, patients with a level above the 90th percentile did not have an increased risk of developing an rMACE compared with patients with platelet reactivity markers below the 90th percentile. Adjustment for potential confounders did not change (CXCL4 and RANTES) or attenuated (NAP-2) the risk estimates even further (Table 1). Changing the cut-off points or using platelet reactivity as continuous variable did not affect the results.

Table 1.   Hazard ratios for recurrent major arterial cardiovascular events (rMACE) in men with a first myocardial infarction (MI) according to platelet reactivity markers
 No rMACE (n = 263)rMACE (n = 238)Hazard ratio (95% CI)
UnadjustedFully adjusted*
  1. Nap-2: neutrophil activating peptide 2; CXCL4: CXC chemokine ligand 4; RANTES: regulated on activation, normal T cell expressed and secreted.

  2. *Adjusted for (at time of blood drawing): age, total cholesterol, systolic blood pressure, current smoking, C reactive protein and use of aspirin, oral anticoagulants, glucose-lowering drugs, cholesterol-lowering drugs.

 < 90th percentile2402111 [ref.]1 [ref.]
  ≥ 90th percentile23271.3 (0.9–1.9)1.1 (0.8–1.7)
 < 90th percentile2392121 [ref.]1 [ref.]
  ≥ 90th percentile24261.2 (0.8–1.8)1.2 (0.8–1.8)
 < 90th percentile2392121 [ref.]1 [ref.]
  ≥ 90th percentile24261.2 (0.8–1.8)1.2 (0.8–1.8)

Our findings in a cohort of men who survived a first MI do not confirm the notion that increased basal platelet reactivity increases the risk of recurrent cardiovascular events. This important negative finding contradicts previous studies which suggested that these inflammatory markers play a role in the development of first and recurrent cardiovascular events [12–17]. Regarding the beta-thromboglobulin NAP-2, our findings are in line with the recent study of Berent et al. [20], in which no difference in the recurrence of cardiovascular events was found between patients with low and high beta-thromboglobulin levels. A possible explanation for the absence of an association between platelet reactivity markers and recurrent cardiovascular events in our study is that our study population represented a group of stable patients with chronic cardiovascular disease, whereas patients in previous studies were studied in an acute setting [13–17]. However, platelet inflammatory markers might play a more dominant role in the development of cardiovascular events in stable patients with a low prevalence of classic risk factors [12]. A major strength of our study is the large sample size and long follow-up, as platelet inflammatory markers may affect the vascular endothelium over a long period of time before a recurrent cardiovascular event takes place. Additionally, our results can be generalized to other men with a first MI, because our cohort was representative of a typical population of men who survived a first MI. A limitation of our study is that renal function, which affects the level of beta-thromboglobulin [21], was not measured and could not be controlled for as a confounding factor. However, because renal function and beta-thromboglobulin are inversely correlated, additionally controlling for the effect of renal function would only attenuate the hazard ratios. Unfortunately, owing to practical reasons, we did not measure soluble glycoprotein Ib (sGPIb) in the present study, whereas a previous study in premenopausal women found an association between high levels of sGPIb and MI [12].

In conclusion, we found that high platelet reactivity, as measured by CXCL4, NAP-2 and RANTES, does not increase the risk of recurrent cardiovascular events in men who survived a first MI.


  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. Disclosure of Conflict of Interests
  5. References

The authors thank the contributors to earlier phases of the Study of Myocardial Infarction Leiden: C.J.M. Doggen, M.D. van der Krabben and the cardiologists of the Departments of Cardiology, Leiden University Medical Center and Hospital Diaconessenhuis Leiden, the Netherlands. The original study, on which the present article is based, was supported by the Netherlands Heart Foundation (grant 92.345). We also thank P.G. de Groot and A.D. Barendrecht of the Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, the Netherlands, who provided the measurements of platelet reactivity markers for this study.

Disclosure of Conflict of Interests

  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. Disclosure of Conflict of Interests
  5. References

The authors state that they have no conflict of interests.


  1. Top of page
  2. Abstract
  3. Acknowledgements
  4. Disclosure of Conflict of Interests
  5. References
  • 1
    Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, et al. Heart disease and stroke statistics 2011 update. Circulation 2011; 123: e18209.
  • 2
    Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, Lansberg MG, Guyatt GH, Spencer FA. Primary and secondary prevention of cardiovascular disease. Chest 2012; 141: e637S68S.
  • 3
    Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006; 113: 236372.
  • 4
    von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100: 2740.
  • 5
    Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 96: 6126.
  • 6
    von Hundelshausen P, Weber KSC, Huo Y, Proudfoot AEI, Nelson PJ, Ley K, Weber C. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001; 103: 17727.
  • 7
    Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A 1981; 78: 45847.
  • 8
    Lane DA, Ireland H, Wolff S, Ranasinghe E, Dawes J. Detection of enhanced in vivo platelet alpha-granule release in different patient groups – comparison of beta-thromboglobulin, platelet factor 4 and thrombospondin assays. Thromb Haemost 1984; 52: 1837.
  • 9
    Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, Hiss E, Ziporen L, Aviram M, Cines D, Poncz M, Higazi AA. Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol Chem 2003; 278: 618793.
  • 10
    Preston RJ, Tran S, Johnson JA, Ni AF, Harmon S, White B, Smith OP, Jenkins PV, Dahlback B, O’Donnell JS. Platelet factor 4 impairs the anticoagulant activity of activated protein C. J Biol Chem 2009; 284: 586975.
  • 11
    Sachais BS, Kuo A, Nassar T, Morgan J, Kariko K, Williams KJ, Feldman M, Aviram M, Shah N, Jarett L, Poncz M, Cines DB, Higazi AA. Platelet factor 4 binds to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in retention of low-density lipoprotein on the cell surface. Blood 2002; 99: 361322.
  • 12
    Snoep JD, Roest M, Barendrecht AD, De Groot PG, Rosendaal FR, van der Bom JG. High platelet reactivity is associated with myocardial infarction in premenopausal women: a population-based case-control study. J Thromb Haemost 2010; 8: 90613.
  • 13
    Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 2007; 27: 92935.
  • 14
    Smith C, Damås JK, Otterdal K, Øie E, Sandberg WJ, Yndestad A, Waehre T, Scholz H, Endresen K, Olofsson PS, Halvorsen B, Gullestad L, Frøland SS, Hansson GK, Aukrust P. Increased levels of neutrophil-activating peptide-2 in acute coronary syndromes: possible role of platelet-mediated vascular inflammation. J Am Coll Cardiol 2006; 48: 15919.
  • 15
    Sobel M, Salzman EW, Davies GC, Handin RI, Sweeney J, Ploetz J, Kurland G. Circulating platelet products in unstable angina pectoris. Circulation 1981; 63: 3006.
  • 16
    Taomoto K, Asada M, Kanazawa Y, Matsumoto S. Usefulness of the measurement of plasma beta-thromboglobulin (beta-TG) in cerebrovascular disease. Stroke 1983; 14: 51824.
  • 17
    Rasi V, Ikkala E, Torstila I. Plasma thromboglobulin in acute myocardial infarction. Thromb Res 1982; 25: 20312.
  • 18
    van der Krabben MD, Rosendaal FR, van der Bom JG, Doggen CJM. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008; 6: 7205.
  • 19
    van Bladel ER, Roest M, De Groot PG, Schutgens RE. Up-regulation of platelet activation in hemophilia A. Haematologica 2011; 96: 88895.
  • 20
    Berent R, Auer J, Franklin B, Schmid P, von Duvillard SP. Platelet response to aspirin 50 and 100 mg in patients with coronary heart disease over a five-year period. The American Journal of Cardiology 2011; 108: 64450.
  • 21
    Andrassy K, Deppermann D, Ritz E, Koderisch J, Seelig H. Different effects of renal failure on beta-thromboglobulin and high affinity platelet factor 4 (HA-PF4)-concentrations. Thromb Res 1980; 18: 46975.